| 新型冠状病毒肺炎相关循环系统血栓防治的药学监护 |
| |
| 引用本文： | 熊堉,蒋敏,边原,凌蔚,童荣生,闫峻峰,龙恩武,陈岷. 新型冠状病毒肺炎相关循环系统血栓防治的药学监护[J]. 华西药学杂志, 2020, 35(3): 347-354. DOI: 10.13375/j.cnki.wcjps.2020.03.022 |
| |
| 作者姓名： | 熊堉 蒋敏 边原 凌蔚 童荣生 闫峻峰 龙恩武 陈岷 |
| |
| 作者单位： | 电子科技大学医学院,四川成都600054;四川省医学科学院·四川省人民医院电子科技大学附属医院药学部个体化药物治疗四川省重点实验室,四川成都610072;四川省医疗卫生服务指导中心,四川成都610042 |
| |
| 基金项目： | 公益性科研院所基本科研业务费专项;四川省人民医院院级科研基金临床研究及转化项目;国家临床重点专科建设项目 |
| |
| 摘 要： | 探索新型冠状病毒肺炎(COVID-19)患者循环系统血栓防治的药学监护策略。对于有心脑血管病史的COVID-19患者需服用抗血小板药物,但需注意与洛匹那韦/利托那韦合用的相互作用影响;对于所有的COVID-19患者需进行VTE风险评估,根据评分模型,除儿童患者外,均可预防性使用相应的抗凝药物。静脉血栓栓塞症(VTE)的治疗可依据临床情况采用溶栓治疗或抗凝药物治疗等,儿童患者可选用达肝素钠和依诺肝素钠。COVID-19相关的循环系统血栓会显著影响患者的预后,在诊疗过程中,应综合救治,动态评估,适时调整策略,并为患者提供必要的药学监护。
|
| 关 键 词： | 新型冠状病毒 新型冠状病毒肺炎 临床药师 循环系统血栓 药学监护 静脉血栓栓塞症 循环系统 |
Pharmaceutical care of COVID-19 associated circulatory system thrombus prevention and treatment |
| |
| XIONG Yu,JIANG Min,BIAN Yuan,LING Wei,TONG Rongsheng,YAN Junfeng,LONG Enwu,CHEN Min. Pharmaceutical care of COVID-19 associated circulatory system thrombus prevention and treatment[J]. West China Journal of Pharmaceutical Sciences, 2020, 35(3): 347-354. DOI: 10.13375/j.cnki.wcjps.2020.03.022 |
| |
| Authors: | XIONG Yu JIANG Min BIAN Yuan LING Wei TONG Rongsheng YAN Junfeng LONG Enwu CHEN Min |
| |
| Affiliation: | (School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan,610054 P.R.China;Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Academy of Medical Sciences,Sichuan Provincial People's Hospital,Affiliated Hospital of University of Electronic Science and Technology of China,Chengdu,Sichuan,610072 P.R.China;Sichuan Provincial Health Service Guidance Center,Chengdu,Sichuan,610042 P.R.China) |
| |
| Abstract: | To explore the pharmaceutical care for the prevention and treatment of circulatory system thrombus during the treatment of COVID-19.For COVID-19 patients with a history of cardiovascular and cerebrovascular diseases,antiplatelet drugs should be taken,but the interaction with lopinavir/ritonavir should be noted.VTE risk assessment was performed on all COVID-19 patients.According to the scores,all patients except children could be prophylactic treated with the corresponding anticoagulant drugs.The treatment of VTE can be based on the clinical situation with thrombolytic therapy or anticoagulant drug treatment,etc.,children can be choosen to use heparin sodium and enoxaparin sodium treatment.COVID-19 associated circulatory system thrombus can significantly affect the prognosis of patients.In the clinical treatment,comprehensive treatment,dynamic assessment,timely adjustment of strategies and necessary pharmaceutical care should be provided. |
| |
| Keywords: | SARS-CoV-2 Corona virus disease 2019 Clinical pharmacist Circulatory thrombus Pharmaceutical services Venous thromboembolism Circulatory system |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
